132 related articles for article (PubMed ID: 25963696)
1. [A female chronic myeloid leukemia patient who gave birth after stopping imatinib intentionally but who maintained a major molecular response with interferon].
Osawa T; Takahashi T; Yasuda M; Umeda M; Nagaya K; Tachi T; Goto H; Kasahara S; Teramachi H; Goto C
Gan To Kagaku Ryoho; 2015 Apr; 42(4):477-9. PubMed ID: 25963696
[TBL] [Abstract][Full Text] [Related]
2. Chronic myeloid leukemia with pregnancy: Successful management of pregnancy and delivery with hydroxyurea and imatinib continued till delivery.
Yadav U; Solanki SL; Yadav R
J Cancer Res Ther; 2013; 9(3):484-6. PubMed ID: 24125987
[TBL] [Abstract][Full Text] [Related]
3. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
4. Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia.
Kobayashi K; Takebayashi C; Miyata S; Narimatsu H; Kami M
Intern Med; 2009; 48(5):369-71. PubMed ID: 19252364
[TBL] [Abstract][Full Text] [Related]
5. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
[TBL] [Abstract][Full Text] [Related]
6. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.
Burchert A; Saussele S; Eigendorff E; Müller MC; Sohlbach K; Inselmann S; Schütz C; Metzelder SK; Ziermann J; Kostrewa P; Hoffmann J; Hehlmann R; Neubauer A; Hochhaus A
Leukemia; 2015 Jun; 29(6):1331-5. PubMed ID: 25712735
[TBL] [Abstract][Full Text] [Related]
8. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D
Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
Kim DD; Hamad N; Lee HG; Kamel-Reid S; Lipton JH
Am J Hematol; 2014 Jun; 89(6):626-32. PubMed ID: 24619861
[TBL] [Abstract][Full Text] [Related]
10. [A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-α].
Wu SH; Zheng CP; Xu J
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):311-5. PubMed ID: 22781725
[TBL] [Abstract][Full Text] [Related]
11. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Branford S; Hughes T; Milner A; Koelmeyer R; Schwarer A; Arthur C; Filshie R; Moreton S; Lynch K; Taylor K
Cancer; 2007 Aug; 110(4):801-8. PubMed ID: 17607681
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
15. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
Aswald JM; Lipton JH; Aswald S; Messner HA
Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054
[TBL] [Abstract][Full Text] [Related]
16. [Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].
Miyashita K; Fujimaki K; Ishigatsubo Y
Gan To Kagaku Ryoho; 2013 Mar; 40(3):405-7. PubMed ID: 23507609
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
18. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Ross DM; Branford S; Seymour JF; Schwarer AP; Arthur C; Bartley PA; Slader C; Field C; Dang P; Filshie RJ; Mills AK; Grigg AP; Melo JV; Hughes TP
Leukemia; 2010 Oct; 24(10):1719-24. PubMed ID: 20811403
[TBL] [Abstract][Full Text] [Related]
19. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
[TBL] [Abstract][Full Text] [Related]
20. The role of interferon-alpha in the treatment of chronic myeloid leukemia.
Kujawski LA; Talpaz M
Cytokine Growth Factor Rev; 2007; 18(5-6):459-71. PubMed ID: 17703986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
